Effect of sustained virological response to interferon therapy for hepatitis C to the hepatectomy for primary hepatocellular carcinoma

Eiji Tsujita, Takashi Maeda, Hiroto Kayashima, Noboru Harada, Shin Ichi Tsutsui, Hiroyuki Matsuda, Nao Kinjo, Yasuharu Ikeda, Masaru Morita, Teruyoshi Ishida

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background/Aims: Interferon (IFN) therapy improves the prognosis of the patients with HCV-related hepatocellular carcinoma (HCC). However, the effects of IFN therapy for hepatectomy (Hx) for primary HCC have not been established. Several published reports investigating the effects of IFN therapy on survival and tumor recurrence after curative resection of HCC have been inconclusive. Methodology: Subjects included 470 patients who underwent Hx for HCV-related primary HCC. One hundred and fifty nine patients received IFN therapy past or postoperatively of the first Hx. Seventy-four of those patients attained a sustained viral response (SVR group). The other 396 patients, including 85 were no responders (NR) and 311 patients who had not received IFN therapy (non-IFN) were classified as the control group. Results: Overall survival (SVR group vs. control group: 5-yr, 93.2 vs. 61.9%; p<0.0001) and disease-free survival (SVR group vs. control group: 5-yr, 56.0 vs. 27.4%; p<0.0001) rates were significantly different. By multivariate analysis, NR/non-IFN was the independent risk factor for overall survival (p=0.0002) and disease-free survival (p=0.0053) after Hx. Conclusions: SVR achieved past or postoperatively to the Hx of HCV-related HCC significantly inhibits recurrence and consequently improves patient survival after Hx for HCC.

Original languageEnglish
Pages (from-to)157-163
Number of pages7
JournalHepato-gastroenterology
Volume62
Issue number137
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Hepatectomy
Hepatitis C
Interferons
Hepatocellular Carcinoma
Survival
Control Groups
Therapeutics
Disease-Free Survival
Recurrence
Multivariate Analysis
Neoplasms

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Effect of sustained virological response to interferon therapy for hepatitis C to the hepatectomy for primary hepatocellular carcinoma. / Tsujita, Eiji; Maeda, Takashi; Kayashima, Hiroto; Harada, Noboru; Tsutsui, Shin Ichi; Matsuda, Hiroyuki; Kinjo, Nao; Ikeda, Yasuharu; Morita, Masaru; Ishida, Teruyoshi.

In: Hepato-gastroenterology, Vol. 62, No. 137, 01.01.2015, p. 157-163.

Research output: Contribution to journalArticle

Tsujita, E, Maeda, T, Kayashima, H, Harada, N, Tsutsui, SI, Matsuda, H, Kinjo, N, Ikeda, Y, Morita, M & Ishida, T 2015, 'Effect of sustained virological response to interferon therapy for hepatitis C to the hepatectomy for primary hepatocellular carcinoma', Hepato-gastroenterology, vol. 62, no. 137, pp. 157-163. https://doi.org/10.5754/hge14749
Tsujita, Eiji ; Maeda, Takashi ; Kayashima, Hiroto ; Harada, Noboru ; Tsutsui, Shin Ichi ; Matsuda, Hiroyuki ; Kinjo, Nao ; Ikeda, Yasuharu ; Morita, Masaru ; Ishida, Teruyoshi. / Effect of sustained virological response to interferon therapy for hepatitis C to the hepatectomy for primary hepatocellular carcinoma. In: Hepato-gastroenterology. 2015 ; Vol. 62, No. 137. pp. 157-163.
@article{33e526a0f24d466480d53f47d0b4ab14,
title = "Effect of sustained virological response to interferon therapy for hepatitis C to the hepatectomy for primary hepatocellular carcinoma",
abstract = "Background/Aims: Interferon (IFN) therapy improves the prognosis of the patients with HCV-related hepatocellular carcinoma (HCC). However, the effects of IFN therapy for hepatectomy (Hx) for primary HCC have not been established. Several published reports investigating the effects of IFN therapy on survival and tumor recurrence after curative resection of HCC have been inconclusive. Methodology: Subjects included 470 patients who underwent Hx for HCV-related primary HCC. One hundred and fifty nine patients received IFN therapy past or postoperatively of the first Hx. Seventy-four of those patients attained a sustained viral response (SVR group). The other 396 patients, including 85 were no responders (NR) and 311 patients who had not received IFN therapy (non-IFN) were classified as the control group. Results: Overall survival (SVR group vs. control group: 5-yr, 93.2 vs. 61.9{\%}; p<0.0001) and disease-free survival (SVR group vs. control group: 5-yr, 56.0 vs. 27.4{\%}; p<0.0001) rates were significantly different. By multivariate analysis, NR/non-IFN was the independent risk factor for overall survival (p=0.0002) and disease-free survival (p=0.0053) after Hx. Conclusions: SVR achieved past or postoperatively to the Hx of HCV-related HCC significantly inhibits recurrence and consequently improves patient survival after Hx for HCC.",
author = "Eiji Tsujita and Takashi Maeda and Hiroto Kayashima and Noboru Harada and Tsutsui, {Shin Ichi} and Hiroyuki Matsuda and Nao Kinjo and Yasuharu Ikeda and Masaru Morita and Teruyoshi Ishida",
year = "2015",
month = "1",
day = "1",
doi = "10.5754/hge14749",
language = "English",
volume = "62",
pages = "157--163",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "137",

}

TY - JOUR

T1 - Effect of sustained virological response to interferon therapy for hepatitis C to the hepatectomy for primary hepatocellular carcinoma

AU - Tsujita, Eiji

AU - Maeda, Takashi

AU - Kayashima, Hiroto

AU - Harada, Noboru

AU - Tsutsui, Shin Ichi

AU - Matsuda, Hiroyuki

AU - Kinjo, Nao

AU - Ikeda, Yasuharu

AU - Morita, Masaru

AU - Ishida, Teruyoshi

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background/Aims: Interferon (IFN) therapy improves the prognosis of the patients with HCV-related hepatocellular carcinoma (HCC). However, the effects of IFN therapy for hepatectomy (Hx) for primary HCC have not been established. Several published reports investigating the effects of IFN therapy on survival and tumor recurrence after curative resection of HCC have been inconclusive. Methodology: Subjects included 470 patients who underwent Hx for HCV-related primary HCC. One hundred and fifty nine patients received IFN therapy past or postoperatively of the first Hx. Seventy-four of those patients attained a sustained viral response (SVR group). The other 396 patients, including 85 were no responders (NR) and 311 patients who had not received IFN therapy (non-IFN) were classified as the control group. Results: Overall survival (SVR group vs. control group: 5-yr, 93.2 vs. 61.9%; p<0.0001) and disease-free survival (SVR group vs. control group: 5-yr, 56.0 vs. 27.4%; p<0.0001) rates were significantly different. By multivariate analysis, NR/non-IFN was the independent risk factor for overall survival (p=0.0002) and disease-free survival (p=0.0053) after Hx. Conclusions: SVR achieved past or postoperatively to the Hx of HCV-related HCC significantly inhibits recurrence and consequently improves patient survival after Hx for HCC.

AB - Background/Aims: Interferon (IFN) therapy improves the prognosis of the patients with HCV-related hepatocellular carcinoma (HCC). However, the effects of IFN therapy for hepatectomy (Hx) for primary HCC have not been established. Several published reports investigating the effects of IFN therapy on survival and tumor recurrence after curative resection of HCC have been inconclusive. Methodology: Subjects included 470 patients who underwent Hx for HCV-related primary HCC. One hundred and fifty nine patients received IFN therapy past or postoperatively of the first Hx. Seventy-four of those patients attained a sustained viral response (SVR group). The other 396 patients, including 85 were no responders (NR) and 311 patients who had not received IFN therapy (non-IFN) were classified as the control group. Results: Overall survival (SVR group vs. control group: 5-yr, 93.2 vs. 61.9%; p<0.0001) and disease-free survival (SVR group vs. control group: 5-yr, 56.0 vs. 27.4%; p<0.0001) rates were significantly different. By multivariate analysis, NR/non-IFN was the independent risk factor for overall survival (p=0.0002) and disease-free survival (p=0.0053) after Hx. Conclusions: SVR achieved past or postoperatively to the Hx of HCV-related HCC significantly inhibits recurrence and consequently improves patient survival after Hx for HCC.

UR - http://www.scopus.com/inward/record.url?scp=84928553948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928553948&partnerID=8YFLogxK

U2 - 10.5754/hge14749

DO - 10.5754/hge14749

M3 - Article

C2 - 25911888

AN - SCOPUS:84928553948

VL - 62

SP - 157

EP - 163

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 137

ER -